These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 9698715)
41. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age. Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232 [TBL] [Abstract][Full Text] [Related]
42. Life-threatening cardiotoxicity due to chronic oral phenytoin overdose. Su CM; Kung CT; Wang YC; Lu CH Neurol India; 2009; 57(2):200-2. PubMed ID: 19439856 [TBL] [Abstract][Full Text] [Related]
43. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Ramsay E; Faught E; Krumholz A; Naritoku D; Privitera M; Schwarzman L; Mao L; Wiegand F; Hulihan J; Epilepsia; 2010 Oct; 51(10):1970-7. PubMed ID: 20633037 [TBL] [Abstract][Full Text] [Related]
44. Three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of phenytoin in an outpatient neurology practice. Spruill WJ; Wade WE; Cobb HH; Akbari S Pharmacotherapy; 2001 Nov; 21(11):1407-14. PubMed ID: 11714214 [TBL] [Abstract][Full Text] [Related]
45. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Wiberg CC Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15851759 [No Abstract] [Full Text] [Related]
46. Paradoxical Seizure Response to Phenytoin in an Epileptic Heroin Addict. Vasagar B; Verma BR; Dewberry RG; Pula T Neurologist; 2015 Jun; 19(6):158-9. PubMed ID: 26075470 [TBL] [Abstract][Full Text] [Related]
47. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Hong JM; Choi YC; Kim WJ Yonsei Med J; 2009 Aug; 50(4):517-20. PubMed ID: 19718399 [TBL] [Abstract][Full Text] [Related]
49. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Mikati M; Bassett N; Schachter S Epilepsia; 1992; 33(2):359-65. PubMed ID: 1547767 [TBL] [Abstract][Full Text] [Related]
50. The relevance of a First-World therapeutic drug monitoring service to the treatment of epilepsy in Third-World conditions. McFadyen ML; Miller R; Juta M; Hodgson V S Afr Med J; 1990 Nov; 78(10):587-90. PubMed ID: 2247792 [TBL] [Abstract][Full Text] [Related]
51. Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling software. Batchelor H; Appleton R; Hawcutt DB Seizure; 2015 Dec; 33():8-12. PubMed ID: 26517379 [TBL] [Abstract][Full Text] [Related]
52. Phenytoin-related ataxia in patients with epilepsy: clinical and radiological characteristics. Shanmugarajah PD; Hoggard N; Aeschlimann DP; Aeschlimann PC; Dennis GJ; Howell SJ; Reuber M; Grünewald RA; Hadjivassiliou M Seizure; 2018 Mar; 56():26-30. PubMed ID: 29427835 [TBL] [Abstract][Full Text] [Related]
53. Single oral loading dose of phenytoin: a pharmacokinetics study. Ratanakorn D; Kaojarern S; Phuapradit P; Mokkhavesa C J Neurol Sci; 1997 Mar; 147(1):89-92. PubMed ID: 9094065 [TBL] [Abstract][Full Text] [Related]
54. Therapeutic drug monitoring in a paediatric epilepsy clinic. Botha J; Bobat RA; Moosa A; Miller R S Afr Med J; 1990 May; 77(10):511-4. PubMed ID: 2343349 [TBL] [Abstract][Full Text] [Related]
55. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa. Valodia P; Seymour MA; Miller R; McFadyen ML; Folb PI Ther Drug Monit; 1999 Feb; 21(1):57-62. PubMed ID: 10051055 [TBL] [Abstract][Full Text] [Related]
56. Charcoal hemoperfusion in an elderly man with life-threatening adverse reactions due to poor metabolism of phenytoin. Sung SF; Chiang PC; Tung HH; Ong CT J Formos Med Assoc; 2004 Aug; 103(8):648-52. PubMed ID: 15340668 [TBL] [Abstract][Full Text] [Related]